The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAkeso, Inc. (9926.HK) announced it has received Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA) to begin clinical trials for AK150. AK150 is a first-in-class trispecific antibody targeting ILT2, ILT4, and CSF1R, specifically designed to treat advanced solid tumors. This milestone marks the first trispecific molecule from Akeso's proprietary technology platform to enter the clinical stage globally. The development aims to address resistance in current cancer immunotherapies through a unique triple-target approach. Investors view this as a significant expansion of the company's oncology pipeline and a validation of its advanced R&D capabilities. The upcoming clinical trials will focus on evaluating the safety and efficacy of the drug in patients with advanced malignancies.